Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56742 | 1.00 | — | — | |
| SCHEMBL3043105 | 1.00 | TSHR (0.41) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL491716 | 1.00 | TSHR (0.41) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL17288070 | 1.00 | TSHR (0.41) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL12483735 | 0.97 | USP2 (0.39) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL491971 | 0.97 | USP2 (0.39) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL8788527 | 0.97 | USP2 (0.39) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL57599 | 0.97 | USP2 (0.39) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL944236 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3074729 | 0.94 | USP2 (0.38) | TSHRUSP2ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11510903-B2 | Synergic pharmaceutical composition of the active enantiomer (S)-ketorolac and Gabapentin for the treatment of neuropathic pain | Amezcua, Federico Amezcua (MX) | 2022-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510903-B2 | Synergic pharmaceutical composition of the active enantiomer (S)-ketorolac and Gabapentin for the treatment of neuropathic pain | OPRK1, OPRD1, GABRA5 | TSHR 4208/4885USP2 3338/4885ALDH1A1 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.